Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,513 matching trials from the live ClinicalTrials.gov search.
Filters: Lexington, Kentucky Clear all
Withdrawn Phase 1Phase 2 Interventional

Traumatic Brain Injury and Effects of Acute Cyclosporine A

NCT02496975
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Cyclosporine A, Placebo
Drug · Other
Lead sponsor
Edward Hall,PhD
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Peer Specialists on VA PACTs

NCT02732600
View directory record Official record
Conditions
Mental Illness, Physical Illness
Interventions
Facilitated Implementation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
25
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting No phase listed Observational

RETHINK REFLUX Registry

NCT04253392
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
LINX Reflux Management System
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
21 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
21
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational Results available

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

NCT04378153
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

Normal Pressure Hydrocephalus (NPH) Registry

NCT00233701
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
Not listed
Lead sponsor
Codman & Shurtleff
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Boulder, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
View directory record Official record
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

NCT03911557
View directory record Official record
Conditions
Tumor, Solid
Interventions
Durvalumab and Tremelimumab
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

NCT02514772
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
39
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Results available

Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation

NCT05270395
View directory record Official record
Conditions
Lung Cancer
Interventions
mPal
Behavioral
Lead sponsor
Laurie McLouth
Other
Eligibility
18 Years to 100 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

NCT03144128
View directory record Official record
Conditions
Cancer Cachexia, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

NCT00569972
View directory record Official record
Conditions
Insomnia
Interventions
PD 0200390, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

NCT02097277
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
BMS-986036, Placebo (Matching with BMS-986036)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart of the Family: A Cardiovascular Disease and Type 2 Diabetes Risk Reduction Intervention in High-Risk Rural Families

NCT04891575
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Active Control Intervention educational sessions, Family Dyad Intervention
Behavioral
Lead sponsor
Gia Mudd
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

NCT00058981
View directory record Official record
Conditions
Diabetes, Autoimmune
Interventions
DiaPep277
Drug
Lead sponsor
DeveloGen Israel, Ltd.
Industry
Eligibility
30 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Fish Oils on Inflammation and Insulin Resistance

NCT00579436
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
omega-3 fatty acid, placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

NCT00483652
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

NCT00343811
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Immediate vs Delayed Placement of Straumann BLX Implants in Molar Extraction Sockets

NCT04327284
View directory record Official record
Conditions
Immediate Placement of Straumann BLX Implants in Molar Extraction Sockets
Interventions
Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm), Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)
Device
Lead sponsor
Ahmad Kutkut
Other
Eligibility
22 Years to 78 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

NCT02785952
View directory record Official record
Conditions
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1201
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
26
States / cities
Scottsdale, Arizona • Beverly Hills, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 21, 2026, 6:59 AM EDT